Apellis Pharmaceuticals, Inc.
Clinical trials sponsored by Apellis Pharmaceuticals, Inc., explained in plain language.
-
New treatment hope for rare kidney disease patients
Disease control APPROVED_FOR_MARKETINGThis program provides early access to pegcetacoplan for people with rare kidney diseases called C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The treatment is for patients aged 12 and older who have active kidney disease and…
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 02, 2026 05:42 UTC
-
Eye drug safety under the microscope in major Real-World study
Disease control OngoingThis study is monitoring the safety and real-world use of Syfovre (pegcetacoplan) injections in patients with geographic atrophy, a condition that causes progressive vision loss from age-related macular degeneration. It will follow 300 patients who are already prescribed this tre…
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC